Which has the lower trailing P/E, INVA or NUTX?

INVA has the lower trailing P/E: INVA trades at 5.10 and NUTX at 8.84. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, INVA or NUTX?

Over the past five years, NUTX grew revenue faster — INVA at a 3.94% CAGR versus NUTX at 37.66%.

Is INVA or NUTX more profitable?

INVA runs the higher net margin — INVA at 80.56% versus NUTX at 21.25%.

How have INVA and NUTX total returns compared?

Over the past 10 years, INVA delivered 6.43% and NUTX delivered -27.99% annualized total return. Past performance doesn't predict future results.

Innoviva, Inc. (INVA) vs Nutex Health, Inc. (NUTX)

A side-by-side comparison of Innoviva, Inc. and Nutex Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

INVA

Innoviva, Inc.

$1.54B

$20.90HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

NUTX

Nutex Health, Inc.

$1.54B

$223.36HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT

Total return — INVA vs NUTX

growth of $100 · dividends reinvested · last 10y

INVA +94.5% (+6.9%/yr)NUTX -96.6% (-28.6%/yr)INVA compounded faster over this window

Log scale — wide-divergence pair

INVA NUTX

INVA vs NUTX: by the numbers

•INVA is the larger company ($1.54B vs $1.54B market cap).
•INVA trades at the lower trailing earnings multiple (5.10 vs 8.84 P/E), one valuation lens rather than an overall verdict.
•INVA converts more revenue to profit (80.56% vs 21.25% net margin).
•NUTX grew revenue faster over the past five years (37.66% vs 3.94% CAGR).

Metrics side by side

Valuation

Metric	INVA	NUTX
P/E ratio	5.10	8.84
Forward P/E	8.64	8.04
PEG ratio	0.49	N/A
P/S ratio	3.48	1.82
P/B ratio	1.25	3.90
EV / EBITDA	4.92	4.36
FCF yield	12.21%	17.84%

Profitability

Metric	INVA	NUTX
Gross margin	73.09%	51.26%
Operating margin	36.66%	31.49%
Net margin	80.56%	21.25%
ROE	28.97%	45.63%
ROIC	8.36%	33.76%

Growth (annualized)

Metric	INVA	NUTX
Revenue CAGR (5Y)	3.94%	37.66%
EPS CAGR (5Y)	12.71%	-14.73%
FCF CAGR (5Y)	-10.54%	N/A
Total return CAGR (5Y)	4.52%	-18.99%

Frequently asked

Which has the lower trailing P/E, INVA or NUTX?: INVA has the lower trailing P/E: INVA trades at 5.10 and NUTX at 8.84. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, INVA or NUTX?: Over the past five years, NUTX grew revenue faster — INVA at a 3.94% CAGR versus NUTX at 37.66%.
Is INVA or NUTX more profitable?: INVA runs the higher net margin — INVA at 80.56% versus NUTX at 21.25%.
How have INVA and NUTX total returns compared?: Over the past 10 years, INVA delivered 6.43% and NUTX delivered -27.99% annualized total return. Past performance doesn't predict future results.

Go deeper

Full INVA analysis Full NUTX analysis Interactive comparison tool

Dig into the metrics

Innoviva P/E ratio Nutex Health P/E ratio Innoviva ROE Nutex Health ROE Innoviva operating margin Nutex Health operating margin Innoviva revenue growth Nutex Health revenue growth Innoviva free cash flow Nutex Health free cash flow

Innoviva & Nutex Health appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.